Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 3
2003 1
2004 1
2008 1
2011 1
2012 1
2013 2
2016 3
2017 2
2018 9
2019 15
2020 15
2021 17
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Results by year
Filters applied: . Clear all
Page 1
Mechanisms of Genomic Instability in Breast Cancer.
Duijf PHG, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna KK. Duijf PHG, et al. Trends Mol Med. 2019 Jul;25(7):595-611. doi: 10.1016/j.molmed.2019.04.004. Epub 2019 May 8. Trends Mol Med. 2019. PMID: 31078431 Review.
HMGA2 as a Critical Regulator in Cancer Development.
Mansoori B, Mohammadi A, Ditzel HJ, Duijf PHG, Khaze V, Gjerstorff MF, Baradaran B. Mansoori B, et al. Among authors: duijf phg. Genes (Basel). 2021 Feb 13;12(2):269. doi: 10.3390/genes12020269. Genes (Basel). 2021. PMID: 33668453 Free PMC article. Review.
Mitotic slippage: an old tale with a new twist.
Sinha D, Duijf PHG, Khanna KK. Sinha D, et al. Among authors: duijf phg. Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2. Cell Cycle. 2019. PMID: 30601084 Free PMC article. Review.
The impact of microRNAs on myeloid-derived suppressor cells in cancer.
Baghbani E, Noorolyai S, Duijf PHG, Silvestris N, Kolahian S, Hashemzadeh S, Baghbanzadeh Kojabad A, FallahVazirabad A, Baradaran B. Baghbani E, et al. Among authors: duijf phg. Hum Immunol. 2021 Sep;82(9):668-678. doi: 10.1016/j.humimm.2021.04.009. Epub 2021 May 18. Hum Immunol. 2021. PMID: 34020831 Review.
Complexities of pharmacogenomic interactions in cancer.
Khanna KK, Duijf PHG. Khanna KK, et al. Among authors: duijf phg. Mol Cell Oncol. 2020 Mar 19;7(3):1735910. doi: 10.1080/23723556.2020.1735910. eCollection 2020. Mol Cell Oncol. 2020. PMID: 32391427 Free PMC article.
Patterns of Genomic Instability in Breast Cancer.
Kalimutho M, Nones K, Srihari S, Duijf PHG, Waddell N, Khanna KK. Kalimutho M, et al. Among authors: duijf phg. Trends Pharmacol Sci. 2019 Mar;40(3):198-211. doi: 10.1016/j.tips.2019.01.005. Epub 2019 Feb 6. Trends Pharmacol Sci. 2019. PMID: 30736983 Review.
The role of miR-34 in cancer drug resistance.
Naghizadeh S, Mohammadi A, Duijf PHG, Baradaran B, Safarzadeh E, Cho WC, Mansoori B. Naghizadeh S, et al. Among authors: duijf phg. J Cell Physiol. 2020 Oct;235(10):6424-6440. doi: 10.1002/jcp.29640. Epub 2020 Feb 16. J Cell Physiol. 2020. PMID: 32064620 Review.
Targeting BRF2 in Cancer Using Repurposed Drugs.
Rashidieh B, Molakarimi M, Mohseni A, Tria SM, Truong H, Srihari S, Adams RC, Jones M, Duijf PHG, Kalimutho M, Khanna KK. Rashidieh B, et al. Among authors: duijf phg. Cancers (Basel). 2021 Jul 27;13(15):3778. doi: 10.3390/cancers13153778. Cancers (Basel). 2021. PMID: 34359683 Free PMC article.
MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy.
Mansoori B, Duijf PHG, Mohammadi A, Safarzadeh E, Ditzel HJ, Gjerstorff MF, Cho WC, Baradaran B. Mansoori B, et al. Among authors: duijf phg. Life Sci. 2021 Jul 1;276:119431. doi: 10.1016/j.lfs.2021.119431. Epub 2021 Mar 27. Life Sci. 2021. PMID: 33785332
64 results